Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced positive pooled continuous glucose monitoring (CGM) data from the pivotal Phase 3 inTandem1 and inTandem2 studies of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced positive pooled continuous glucose monitoring (CGM) data from the pivotal Phase 3 inTandem1 and inTandem2 studies of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor.